Skip to main content

Table 7 Elderly AML front-line treatment options and median OS times

From: Azacitidine front-line in 339 patients with myelodysplastic syndromes and acute myeloid leukaemia: comparison of French-American-British and World Health Organization classifications

Treatment N Age, years Median age, years CR/CRi, % OS, mo Phase Ref
Untreated 3367 ≥65 77 n.g. 2 Retrosp. [39]
HU+/-ATRA 99a >60 74 1 ~3 III [43]
HD-LEN 33 >60 71 30 4 II [45]
LD-AraC+/-ATRA 103a >60 74 18 <5 III [43]
CFA 112 >60 71 46 9.4 II [40]
CFA + LD-AraC 54 >60 71 63 11.4 II [42]
CFA + LD-AraC/DAC 60 >60 70 58 12.7 II [44]
CFA + LD-AraC/DAC 118 >60 68 60 11.1 II [44]
Allo-SCT 46 ≥65 67 n.g. 22 Retrosp. [39]
Intensive CTX 1856 ≥65 74 n.g. 6 Retrosp. [39]
Intensive CTX (3 + 7) 416 >65 67 57 12 III [41]
BSC ↔ allo-SCT 352 ≥60 n.g. n.g. 9.0 Retrosp. [47]
BSC ↔ allo-SCT 5480 ≥65 78 n.g. 3.0 Retrosp. [39]
DAC (DACO-16) 238 >65 74 18 7.7 III [48]
AZA (AZA-AML-001) 241 >65 75 28 10.4 III [24]
AZA-AAR 193 >17 77 18 12.6 Retrosp. [46]
AZA + LEN 42 >60 74 28 15.9 I/II [38]
  1. aIncluded 14 patients with high-risk MDS
  2. n.g. CR complete response, CRi CR with incomplete blood count recovery, OS overall survival, n.g. not given, HU hydroxyurea, ATRA all trans retinoic acid, HD high-dose, LEN lenalidomide, LD-AraC low-dose cytarabine, CFA clofarabine, DAC decitabine, allo-SCT allogeneic stem cell transplantation, CTX chemotherapy, BSC best supportive care, AZA azacitidine, AML acute myeloid leukaemia, AAR Austrian Azacitidine Registry, MDS myelodysplastic syndrome